TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today reported that the Baltimore Sun has published an article written by Stephanie Desmon profiling Revimmune™ (high-dose cyclophosphamide) and reports on studies conducted by Johns Hopkins University researchers showing treatment with Revimmune demonstrates remarkable promise for the elimination of transplant rejection, including bone marrow transplant usage to cure chronic illnesses such as sickle cell anemia.
